For pharma marketers, MLR review can take much longer than expected and delay campaign launch. But that review time doesn’t necessarily have to be lost.

VG Health gives marketers the option to begin gathering voluntary patient feedback as zero-party data while branded creative is still moving through review. Those early signals can help reveal where patients are in their journey, what they need, and which audiences may be most relevant to reach. 

Once branded assets are approved, those learnings can become part of a broader activation strategy.

The impact can be significant: In one recent rare disease campaign, this strategy drove 3.2x higher Engaged Site Reach and a 2.2x higher Crossix Audience Quality Score than the partner average. 

The key is knowing what to ask and how to use the response signals effectively.

Want to learn more? Get in touch and we’ll show you how VG Health can fit into your media and MLR process.